Mynx Cadence, with its simpler three design changes, provides improved ease-of-use and utilizes a conformable, water-soluble polyethylene glycol (PEG) sealant to seal the femoral artery, which dissolves within 30 days, leaving nothing behind but a healed artery, the company said.
The new sealant sleeve protects the sealant during deployment and shortens the procedure time by eliminating the need to pre-soak during device preparation and the changes result in more consistent sealant delivery every time.
The US Food and Drug Administration approved Mynx is available in two sizes for 5F and 6F/7F procedural sheaths.
AccessClosure president and CEO Gregory Casciaro said the designing enhanced solutions for vascular closure is their priority and the design changes incorporated into the Mynx Cadence make it easier to use while maintaining the same feel their users have grown accustomed to.
"We believe this device provides an excellent platform for growth as we continue to expand our user base," Casciaro said.
